Real-time, Multidisciplinary Approach of Women With Pregnancy-Associated Thrombotic Microangiopathy Authors: Nelson-Georges Dengo, Charlotte Ferrier, Thomas Robert, Yahsou Delmas, Steven Grangé, François Provot, Mathias Rossignol, Mercédès Jourdain, Vincent Dupont, David Desseauve, Véronique Frémeaux-Bacchi, Vassilis Tsatsaris, Anthony Atallah, Pierre-François Ceccaldi, Mary-Jane Guerry, Bérangère Joly, Anne-Sophie Bouthors, Christelle Fosso, Anne Leostic, Anne Grunenwald, Andrew Carlin, Sophie Hillaire, Manon Marie, Paul Coppo, Alexandre Hertig, French National Multidisciplinary Consultation Committee on Thrombotic Microangiopathy and Pregnancy Published: 2026 ABSTRACT AbstractIntroductionThrombotic microangiopathies (TMAs) occurring during pregnancy or the immediate postpartum period are a rare, and highly complex syndrome. Determination of the most appropriate therapeutic strategy remains challenging and requires individualized assessment.MethodsTo support both diagnostic and therapeutic decision-making, a national multidisciplinary consultation committee [MCC] (titled “TMA and Pregnancy”) was established in October 2023 under the auspices of the French National Reference Center for TMAs. The MCC is activated for a single case, on an emergency basis, and within 24 hours. It brings together national experts from 8 medical specialties.ResultsHere, we report on 2 years of experience of the MCC, including operational aspects, activity indicators, the clinical and obstetrical profiles of the first 76 women whose cases were reviewed, the suspected diagnoses, and the real-time impact on patient management. Of the women, 29 (38%) were primiparous. The obstetrical context was preeclampsia in 47% and peripartum hemorrhage (PPH) in 40% of the women. TMA was most frequently attributed to severe endotheliosis, with acute kidney injury (AKI) present in 47 women (62%), including 9 (12%) showing renal cortical necrosis (RCN). Thrombotic thrombocytopenic purpura (TTP) was relatively uncommon (n = 13, 17%), and no cases were considered to represent atypical hemolytic and uremic syndrome (aHUS). The MCC led to a change in management in 26% of cases, most often a deescalation of therapy.ConclusionWe emphasize the value of real-time multidisciplinary case conferences in managing catastrophic obstetrical syndromes and advocate for the recognition of extreme phenotypes of endotheliosis extending beyond the liver. These findings underscore the need for therapies targeting endothelial injury.Keywords: acute kidney injury, endotheliosis, preeclampsia, pregnancy, thrombotic microangiopathy In parturient women, the occurrence of a life-threatening obstetrical condition such as PPH or severe preeclampsia is often associated with anemia and thrombocytopenia. Both can be explained by hemorrhage, or by hemolysis in preeclamptic women developing Hemolysis Elevated Liver function tests and Low Platelets (HELLP) syndrome. However, the possibility of a flare of a more specific TMA such as TTP, or aHUS, for example,1 must be considered. Differential diagnosis is of paramount importance because TTP and aHUS do not resolve with delivery or transfusion of red blood cells: if untreated, they may lead to cerebral or renal death, respectively. Because pregnancy is a well-known trigger of immune-mediated and even hereditary TTP,2 and delivery is a well-known trigger of aHUS,3 sophisticated treatments are sometimes initiated (e.g., plasma exchange and more recently, recombinant ADAMTS-13,4,5 or anti-C5 monoclonal antibodies6) and continued until diagnosis is confirmed or refuted. Therefore, it is the possibility of specific renal TMA that pushes clinicians to empirically treat a putative worst-case scenario. Given this complexity, a French national MCC was established in October 2023 to provide emergency support, within 24 hours of referral, to clinicians from France and Belgium, managing these patients. Here, we report on our experience after 2 years of activity. Methods Structure and Organization of the MCC The MCC was established at a national level under the auspices of the French National Reference Center for TMA to provide real-time support to clinicians managing pregnant women or women in the immediate postpartum period presenting with TMA syndrome in either physiological or pathological obstetrical contexts. This MCC complied with the recommendations of the French National Authority for Health,7 in that all opinions issued were systematically summarized in a dated written report and sent within 24 hours, allowing proper documentation in the patient’s medical records. Quality indicators were defined from the outset, including the number of meetings held, the number and specialties of participating experts, and regular updating of typical clinical scenarios encountered. However, the pathological context in which the MCC has been operating has prevented strict adherence to 1 recommendation: holding meetings at regular intervals. By necessity, the MCC convened a care conference on an urgent, case-by-case basis (in practice, within 24 hours of an external request for expertise, 7 d/wk), because of the need to promptly establish an etiological diagnosis and recommend the most appropriate therapeutic strategy (the MCC provides advisory recommendations and is not legally binding). Each opinion includes a diagnostic component (e.g., was this truly a TMA syndrome, and if so, what was the most likely mechanism?) and a therapeutic component aimed at resolving the TMA. In addition, practical recommendations were provided regarding the mode of delivery, anticoagulation, blood pressure control, transfusion thresholds (for red blood cells and platelets), breastfeeding, contraception, and other aspects of clinical management. The creation of the MCC was first announced in Paris, France, at the annual French National Reference Center for TMA meeting on October 21, 2023, and subsequently presented at local (departmental meetings) and national events (scientific conferences and congresses). Seventy-four experts from 8 specialties (obstetrics and gynecology; anesthesiology and intensive care; nephrology; laboratory medicine, including hemostasis, complement, and ADAMTS-13 biology; internal medicine; hepatology; hematology; and immunology) were progressively recruited on the basis of their involvement in pregnancy-related complications. They all volunteered to participate on an unpaid basis in unscheduled meetings, potentially outside regular working days. Requests for care conference review were submitted by email (rcpmatgrossesse@hopital-foch.com). Referring physicians were required to provide a core set of clinical data, including blood pressure trends, proteinuria levels, and a detailed obstetric history. The Meetings were held via videoconference, using Zoom. Meeting times were scheduled in coordination with the referring physician, according to their availability. This, together with the inherently unpredictable nature of these meetings, explains why no minimum quorum was initially required to hold a meeting, with the expectation that a sufficient number of experts would usually be able to attend. Diagnosis of preeclampsia and related disorders was based on the International Society for the Study of Hypertension in Pregnancy recommendations updated in 2021.8 Recommendations were formulated through multidisciplinary discussion until consensus was reached among the participating experts. Legal Aspects Physicians participating in each care conference were professionally liable, because the cases discussed were severe and the decisions may influence the vital prognosis of the mother, the fetus, or the newborn. In the event of litigation, each physician was covered by their own professional civil liability insurance, rather than by the hospital they were employed by. For this reason, all participating physicians must hold up-to-date professional insurance coverage, and the names of physicians attending the care conference was documented in the meeting report. Importantly, though the MCC provided expert advisory input, ultimate responsibility for therapeutic decisions remains with the treating physician, who must integrate the care conference recommendations with the patient’s evolving clinical condition. Ethical Aspects Authorization to collect data on patients discussed during the “TMA and Pregnancy” care conference was submitted to the Research Ethics Committee of Foch Hospital, which issued a favorable opinion on March 19, 2025 (IRB00012437). Regulatory Aspects The MCC report reminded the referring clinicians that they were responsible for informing the patient that her case was discussed during a multidisciplinary meeting, for incorporating the written report into the medical record; and should the final therapeutic decision differ from the care conference recommendations, for documenting and justifying this deviation in the medical records. Statistical Analysis and Data Visualization Continuous variables were assessed for normality using the Shapiro-Wilk test. Given the nonnormal distribution of most clinical parameters, data were presented as median, interquartile range. Categorical variables were reported as absolute numbers and frequencies (%). Differences between groups were analyzed using the 2-sided Fisher exact test for categorical data and the Mann-Whitney U test for continuous variables. Missing data were handled using pairwise deletion, and no imputation was performed. Statistical significance was defined as a 2-tailed P-value < 0.05. All statistical analyses and high-resolution visualizations were conducted using Python (version 3.12). We used the SciPy (v1.11) library for inferential statistics and Pandas (v2.1) for data management. Geographical distribution maps were generated using GeoPandas (v0.14) to ensure cartographic precision, whereas all other figures were produced using the Matplotlib and Seaborn libraries (Supplementary Methods). Results Descriptive Overview Between October 23, 2023 and February 5, 2026, care conferences were convened on 76 occasions, for women hospitalized in France including oversease territories (Supplementary Figure S1). Each meeting lasted between 30 and 60 minutes. Seven meetings (9%) were held outside regular working days. The mean number of participating experts increased over time were as follows: 10 in 2023, 13 in 2024, and 15 in 2025 (Supplementary Figure S2). This was paralleled by an increase in the mean number of medical specialties represented at each meeting (3.9 in 2023, 4.3 in 2024, and 5 in 2025). A care conference was convened electively, outside of an acute context, in anticipation of a future pregnancy deemed at high risk of TMA, to optimize preventive management (for example, early in pregnancy in a woman with a prior history of aHUS). Obstetrical Context And Organ Dysfunction Characteristics of the patients discussed during the care conference are summarized in Table 1, and their main biological features in Tables 2 and 3. One-third of the care conferences (38%) concerned complications occurring during a first pregnancy. In most cases (70%), the multidisciplinary discussion took place in the postpartum period, at a median of 5 days after delivery. Overall, 47% of patients were presented to the MCC as having preeclampsia, either isolated or associated with other conditions (32% had HELLP syndrome). PPH occurred in 40% of cases, and 11% experienced placental abruption. In this initial cohort, there was 1 maternal death (in a woman with sickle cell disease [HbSC genotype], who was already in multiorgan failure at the time of the care conference; death occurred as a result of a vaso-occlusive crisis), 10 intrauterine fetal deaths, and 1 infant death in the immediate postnatal period. Two patients met diagnostic criteria for acute fatty liver of pregnancy, and 1 woman had suspected amniotic fluid embolism. AKI was present in 62% of cases (all Kidney Disease: Improving Global Outcomes stages combined; the median Kidney Disease: Improving Global Outcomes stage was 3). Among all AKI patients, 45% required renal replacement therapy with hemodialysis. AKI was significantly more frequent in women with PPH (93.3%) than in those with isolated preeclampsia (62.5%, P = 0.017, Table 4). Among patients with PPH, the median volume of hemorrhage was significantly higher in the isolated PPH group than in the combined PPH–preeclampsia group (1500 [interquartile range: 1125–2000] ml vs. 850 [interquartile range: 625–1650] ml, P = 0.02; Table 4). RCN was observed in 50% of isolated PPH cases, compared with 6.2% in preeclamptic women with or without PPH. Table 1Clinical characteristics of the entire cohort (N = 76)CharacteristicsTotal population (N = 76)Maternal charcteristicsAge (yrs), median, IQR31, 28–36Primiparity, n (%)29 (38.2%)ComorbiditiesHypertension, n (%)3 (3.9%)History of aHUS, n (%)2 (2.6%)Chronic kidney disease, n (%)1 (1.3%)ObstetricsTerm (WG), mean ± SD31.3 ± 8.0Diagnosis (trigger)Preeclampsia, n (%)36 (47.4%)HELLP Syndrome, n (%)24 (31.6%)PPH, n (%)30 (39.5%)Placenta abruptio, n (%)8 (10.5%)Cumulative conditionsPreeclampsia + HELLP, n (%)24 (31.6%)Preeclampsia + PPH, n (%)16 (21.1%)Preeclampsia + HELLP + PPH, n (%)10 (13.2%)Associated diagnosisSepsis, n (%)1 (1.3%)Amniotic fluid embolism, n (%)1 (1.3%)VItamin deficiency (B12/folates), n (%)1 (1.3%)Renal failureAKI, n (%)47 (61.8%)KDIGO stage 3, n (%)31 (40.8%)Hemodialysis, n (%)21 (27.6%)DiagnosisEndotheliosis46 (60.5%)Isolated endotheliosis36 (47.4%)Renal cortical necrosis9 (11.8%)Primary TMA13 (17.1%)Idiopathic TTP7 (9.2%)Suspicion of congenital TTP6 (7.9%)Others17 (22.4%)Severe hypertension5 (6.6%)Sepsis (DICV)1 (1.3%)Drug toxicity1 (1.3%)Venous TMA1 (1.3%)No TMA9 (11.8%)aHUS, atypical hemolytic and uremic syndrome; AKI, acute kidney injury; HELLP, Hemolysis Elevated Liver function tests and Low Platelets syndrome; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura; WG, wks of gestation.Values are expressed as median (interquartile range: 25%–75%) for quantitative variables and as number (percentage) for qualitative variables. Clinical characteristics of the entire cohort (N = 76) aHUS, atypical hemolytic and uremic syndrome; AKI, acute kidney injury; HELLP, Hemolysis Elevated Liver function tests and Low Platelets syndrome; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura; WG, wks of gestation. Values are expressed as median (interquartile range: 25%–75%) for quantitative variables and as number (percentage) for qualitative variables. Table 2Biology in the total cohort, collected on the day of the MCCBiological variablesMedian, IQRNormal range (during pregnancy)Haemoglobin (g/dl)7.8 (6.8–9.4)11–12.9Reticulocytes (G/l)98.5 (65–140)20–120Schistocytes (%)1.2 (0–2)< 1.9LDH (UI/l)1107 (287–2247)125–220Haptoglobin (gr/l)0.0 (0.0–0.03)0.35–2.5Platelets (G/l)62 (37–114)150–300Creatinine (μmol/l)169 (77–500)64–104ASAT (UI/l)68 (38–433)5–34ALAT (UI/l)63 (32–233)< 55Bilirubine (μmol/l)14 (6–42)3–20Prothrombin time (%)98 (89–100)100–120activated partial thromboplastin time (aPTT ratio)1.04 (0.96–1.28)0.8–1Fibrinogen (g/l)3.4 (2.6–4.8)4.5–5.5Factor V (%)91 (48–116)100–140Troponin (ng/ml)25 (11–710)< 0.04ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; IQR, interquartile range; LDH, lactate dehydrogenase. Biology in the total cohort, collected on the day of the MCC ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; IQR, interquartile range; LDH, lactate dehydrogenase. Table 3Clinical and biological characteristics by diagnostic group (N = 55)ParameterEndotheliosis-TMA (n = 33)TTP (n = 13)Renal cortical necrosis (n = 9)Clinical outcomesAKI, n (%)29 (87.9%)0 (0.0%)9 (100.0%)Dialysis, n (%)9 (27.3%)0 (0.0%)8 (88.9%)HematologyHemoglobin (g/dl)6.86.3–8.1 (n = 32)7.86.6–10.9 (n = 11)6.66.0–7.6 (n = 9)Platelet count (G/l)37.025.0–61.0 (n = 33)21.011.5–47.5 (n = 11)37.030.0–72.0 (n = 9)Schistocytes (%)1.30.7–2.9 (n = 30)1.40.5–1.9 (n = 10)2.21.9–2.6 (n = 8)Haptoglobin (g/l)0.10.1–0.1 (n = 31)0.10.1–0.3 (n = 11)0.10.1–0.1 (n = 9)LDH (UI/l)1738825–2900 (n = 31)790320–951 (n = 9)35002848–3891 (n = 7)Renal & liver functionSerum creatinine (μmol/l)232.5136–500 (n = 32)62.060–68 (n = 9)500.0500–624 (n = 9)Proteinuria (g/g)2.01.1–4.1 (n = 27)1.30.5–4.0 (n = 8)7.04.5–8.4 (n = 7)ASAT (UI/L)347.095–702 (n = 31)40.528–86 (n = 8)336.0300–436 (n = 9)ALAT (UI/L)132.030–702 (n = 31)30.025–35 (n = 7)110.530–182 (n = 8)Total bilirubin (μmol/l)18.59–97 (n = 16)10.05–10 (n = 5)20.210–41 (n = 6)CoagulationProthrombin time (%)93.072–100 (n = 25)100.099–118 (n = 7)90.087–100 (n = 9)Fibrinogen (g/l)2.91.8–4.0 (n = 23)3.72.8–4.7 (n = 6)3.91.9–4.6 (n = 8)Specific markersADAMTS13 activity (%)61.743–73 (n = 25)2.52.2–5.1 (n = 10)43.535–48 (n = 6)sFlt-1/PlGF ratio64.045–400 (n = 7)157.0157–157 (n = 1)360.0180–540 (n = 2)Complement systemC3 (g/l)1.21.0–1.2 (n = 19)1.51.2–1.7 (n = 4)0.80.7–0.9 (n = 5)C4 (g/l)0.20.2–0.3 (n = 18)0.30.2–0.3 (n = 4)0.10.1–0.2 (n = 4)ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; LDH, lactate dehydrogenase; PlGF, placental growth factor; RCN, renal cortical necrosis; TTP, thrombotic thrombocytopenic purpura.Data are presented as median interquartile range or n (%). n represents the number of patients with available data for each parameter. Clinical and biological characteristics by diagnostic group (N = 55) ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; LDH, lactate dehydrogenase; PlGF, placental growth factor; RCN, renal cortical necrosis; TTP, thrombotic thrombocytopenic purpura. Data are presented as median interquartile range or n (%). n represents the number of patients with available data for each parameter. Table 4Impact of obstetrical context on renal severityPPH + Preeclampsia (n = 16)PPH only (n = 12)Isolated preeclampsia (n = 16)P-valueaHemorrhage volume (ml) median, IQR850625–165015001125–20000.02AKI (n, %)15 (93.8%)11 (91.7%)10 (62.5%)0.017Severe AKIb, n (%)12 (75.0%)7 (58.3%)8 (50.0%)0.336RCN (n, %)1 (6.2%)6 (50.0%)1 (6.2%)0.128AKI, acute kidney injury; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes; PPH, postpartum hemorrhage; RCN, renal cortical necrosis.aP-value compares any PPH (n = 28) vs. isolated preeclampsia (n = 16) using Fisher exact test. P < 0.05 indicates statistical significance.bSevere AKI is defined as KDIGO stage 3 or requirement for renal replacement therapy (dialysis). Impact of obstetrical context on renal severity AKI, acute kidney injury; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes; PPH, postpartum hemorrhage; RCN, renal cortical necrosis. P-value compares any PPH (n = 28) vs. isolated preeclampsia (n = 16) using Fisher exact test. P < 0.05 indicates statistical significance. Severe AKI is defined as KDIGO stage 3 or requirement for renal replacement therapy (dialysis). MCC Conclusions Regarding the Primary Mechanism of TMA The diagnoses proposed following the care conferences are summarized in Table 1 and illustrated according to gestational age in Figure 1. Bicytopenia was considered to be secondary to the obstetrical context (preeclampsia, and/or PPH with or without partial or diffuse RCN visible on imaging) in the majority of women (n = 46, 61%). Some patients presented with >1 concomitant obstetrical condition (Figure 2). Primary TMA was less frequently suspected. TTP was diagnosed in 13 patients (17%), including 5 cases immediately identified as immune-mediated based on the detection of anti-ADAMTS-13 antibodies, 2 considered idiopathic in the absence of detectable antibodies, and 6 considered suggestive of hereditary TTP because of occurrence during a first pregnancy and the absence of detectable antibodies. With regard to the retained mechanisms of pregnancy-associated TMA, the presentation of TTP was almost exclusively hematological, whereas severe preeclampsia showed a clearly systemic pattern, as illustrated by Figure 3. None of the patients was considered to have developed a spontaneous inaugural episode of aHUS with absolute certainty. We retained a diagnosis of severe hypertension in 2 women who developed severe hypertension before 20 weeks of gestation, and in 3 additional women with a prior history of chronic hypertension who presented with severe hypertension at the time of the MCC but no evidence of acute organ injury despite the TMA syndrome. In the absence of placental histology at the time of the MCC discussion, we acknowledged that preeclampsia could not formally be excluded as the underlying cause. Among rarer causes, 1 case of renal arcuate vein microthrombi (reported9) and 1 metabolic defect involving the cobalamin C pathway were identified. In 9 patients, the MCC concluded that no TMA was present at the time of the meeting. Distribution of retained diagnoses by gestational age. TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura. Sunburst diagram illustrating the hierarchical classification of the final diagnoses according to the obstetrical context. The inner ring represents the primary obstetrical context (preeclampsia, spontaneous, PPH, or sepsis). The outer ring details the underlying TMA mechanism or final diagnosis as determined by the Multidisciplinary Consultation Committee. Each mechanism is color-coded as a specific shade of its corresponding inner context to ensure visual alignment. Total cases (n = 75) are categorized, with 1 case (Mons) excluded from the final analysis. AFLP, acute fatty liver of pregnancy; cTTP, congenital TTP; DIC, disseminated intravascular coagulation; Endotheliosis-TMA, pregnancy-associated TMA; iTTP, immune TTP; PPH, postpartum hemorrhage; RCN, renal cortical necrosis; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura. Biological radar phenotypes of the 3 primary pregnancy-associated TMA entities. This radar chart illustrates the distinct clinical signatures of gravid TMA (red), TTP (green), and renal cortical necrosis (blue). Each axis represents a normalized clinical severity scale (0–1) based on established diagnostic thresholds. For parameters where a lower value indicates higher severity (platelets, ADAMTS13 activity, and fibrinogen), values are inverted so that the outer edge consistently represents maximum clinical impact. The systemic multiorgan involvement of gravid TMA contrasts with the pure hematological pattern of TTP and the catastrophic renal-hemolytic failure of cortical necrosis. Methodology for the construction of this chart is explained in supplementary material. LDH, lactate dehydrogenase; RCN, renal cortical necrosis; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura. MCC Recommendations Regarding Therapeutic Strategy All therapeutic recommendations reached by consensus at the conclusion of the care conferences are illustrated in Figure 4, showing whether the recommendation corresponded to continuation of no specific therapy (referred to as active surveillance) or to a modification of treatment (escalation, or deescalation). Overall, the MCC recommended a change in management in 20 patients (26% of cases). Specifically, a targeted therapeutic intervention was recommended in 5 women (7%) who had initially been managed with surveillance alone. Conversely, in 15 women (19%) receiving a specific treatment, the MCC recommended its discontinuation and reverting to active surveillance. As shown in Figure 1, in the majority of cases the MCC concluded that the TMA was attributable to the obstetrical context and that, based on current knowledge, there was no indication to initiate or continue specific therapies. Recombinant ADAMTS-13 was recommended in 4 women suspected of experiencing a flare of hereditary TTP, and in 1 patient with a severe flare of immune-mediated TTP refractory to all available therapies (this case has since been reported also, as the first documented use of recombinant ADAMTS-13 in this context5). Similarly, eculizumab was either continued (as a prophylactic measure in 1 woman without TMA but with a history of aHUS because of a pathogenic CD46 variant) or newly recommended, not because a flare of aHUS was suspected, but for other reasons: in 2 cases, in the setting of PPH complicated by RCN, based on a putative mechanistic rationale6; in another case, in a woman with severe hypertension and a critical clinical condition. On only 1 occasion did the group recommend that the local team consider therapeutic termination of pregnancy in the interest of the mother, at a gestational age too early to allow the birth of a viable infant. Alluvial diagram showing the therapeutic strategy before MCC meeting (left) and the recommendations issued by the MCC (right). This diagram was generated by the Numiqo platform. CAPLA, caplacizumab; GC, glucocorticoids; MCC, multidisciplinary consultation committee; PE, plasma exchange; PLA, plasma; rADAMTS13, recombinant ADAMTS-13; RTX, rituximab. Discussion This is the first description of the French national MCC dedicated to “TMA and Pregnancy.” This MCC has a distinctive feature: it can be activated within 24 hours, including on weekends and public holidays. To our knowledge, no comparable structure currently exists nationally or internationally. The cases discussed during the first 2 years of activity shared the following 3 main characteristics: (i) complexity of obstetrical context, often involving overlapping conditions; (ii) high frequency of renal failure, frequently severe, often leading to suspicion of aHUS, but this latter diagnosis was never retained; and (iii) added value of multidisciplinary expertise in formulating a therapeutic strategy balancing the interests of both mother and child. Thus, a change in patient’s management was recommended in 26% of the cases, mostly as a deescalation, because endotheliosis was considered the main mechanism of TMA. A striking finding in our cohort was the high prevalence of severe AKI, particularly in preeclamptic women with relatively low volumes of blood loss during PPH. This underscores the heightened vulnerability of the renal microvasculature during pregnancy. The current nosology surrounding what is commonly termed “pregnancy-related TMA”1,3 suggests a single umbrella entity encompassing heterogeneous etiologies, such as preeclampsia (in which TMA lesions are classically thought to localize in the liver and AKI is attributed to acute tubular necrosis10,11), aHUS, and TTP. However, preeclampsia and PPH represent sufficiently profound endothelial insults to induce true intrarenal TMA.12 In the available literature, the retrospective identification of a pathogenic variant in genes encoding the alternate complement pathaway in such obstetrical contexts is very uncommon (in contrast with the “general” population of patients developing aHUS, where a pathogenic genetic variation is found in 60% of the cases occurring outside the context of pregnancy,13 the proportion has repeatedly been found to be low in “pregnancy-related TMA”, ∼10%).6,14,15 Actually, in the seminal description of HELLP syndrome,16 AKI was present in 57% of women. AKI does not appear in the acronym because it was not constant and therefore was not considered a defining criterion. We can only speculate that the original definition of HELLP may have led clinicians to localize TMA lesions primarily in the liver, with AKI considered a secondary complication. This interpretation is understandable, because it corresponds to the prototypical presentation of TMA in preeclampsia. However, it is incomplete, because HELLP syndrome multiplies the risk of AKI by 5,17 and in clinical practice AKI is diagnosed in ≥15% of women affected by HELLP syndrome.18,19 A later study concluding that HELLP-associated AKI results from acute tubular necrosis may have further reinforced this view, although that study did not include histological examination of the kidneys.10 However, endothelial injury of preeclampsia may go far beyond mild endotheliosis and proteinuria.20,21 A few years after the first description of glomerular endotheliosis by Farquhar et al.22 in 1954, glomerular fibrin staining during preeclampsia was reported21 (as well as in cerebral capillaries, incidentally23). We subsequently learned from the study by Strevens et al.24 that even normal pregnancy may be associated with mild glomerular endotheliosis. The concept of a systemic, preeclampsia-related glomerular TMA aligns with previous observations by nephrologists and renal pathologists,20 as well as with the well-established pathophysiology of glomerular injury in preeclampsia.25 Importantly, recognizing endotheliosis-associated TMA as a distinct entity does not in any way exclude a central role for complement activation. Serum from women with preeclampsia has been shown to induce complement deposition on cultured endothelial cells,26 and sFlt-1–mediated sequestration of placental growth factor (PlGF) has been reported to reduce endothelial synthesis of factor H,27 the major regulator of the alternative complement pathway. In addition, free heme released during hemolysis in HELLP syndrome has been shown to alter the glycocalyx of glomerular endothelial cells, thereby impairing factor H binding and complement.12 For these reasons, we believe that complement biology should be systematically explored in severe cases of endotheliosis-associated TMA, and that complement inhibitors warrant evaluation in prospective interventional studies. Overall, we propose that the differential diagnosis of pregnancy-associated TMAs should be guided primarily by the obstetrical context, with definitive etiologies confirmed by specific biological tests (Supplementary Table S1). Three syndromes would emerge as follows: (i) endotheliosis-related TMA, in which HELLP syndrome and AKI, occurring either alone or in combination, can reasonably be explained by preeclampsia, and where RCN would be an extreme phenotype, often aggravated by the judicious use of procoagulant and anti-fibrinolytic drugs; (ii) aHUS (which typically occurs postpartum after an otherwise uncomplicated pregnancy); and (iii) TTP (whether immune-mediated or of unknown origin, the latter including previously unrecognized hereditary TTP, which typically manifests during the first pregnancy). RCN is very much related to the gravid state; an association that was experimentally demonstrated as early as early twentieth century.28 In that, anatomical lesions affect larger arteriolar vessels upstream of the glomerular capillary bed.29 Women experiencing PPH may develop “acute obstetrical coagulopathy,”30 characterized by hypofibrinogenemia, dysfibrinogenemia, and massive fibrinolysis, which often leads clinicians to administer procoagulant and antifibrinolytic agents in an effort to save maternal lives. Tranexamic acid, which has a low molecular weight, may accumulate when AKI develops and thereby increase, in a vicious cycle, the likelihood of intrarenal thrombosis.14 Here again, this phenomenon appears specific to parturient women receiving high doses of tranexamic acid, because no signal of renal injury has been reported in women receiving a maximum dose of 2 g of this drug,31 or in trauma patients.32 From this perspective, our data are informative. Outside pregnancy, a decrease in blood pressure typically occurs only after blood loss exceeding approximately 30% (∼ 1500–2000 ml),33,34 which may then explain the development of AKI. However, in our cohort, AKI was observed in association with substantially lower volumes of blood loss, particularly when preeclampsia was present (in these cases, the mean estimated blood loss was only 850 ml). Antiangiogenic factors were rarely measured (moreover, interpretation of the sFlt-1/PlGF ratio would likely be confounded by plasma infusion, and by hemodialysis, because of the low molecular weight of PlGF). We can therefore only speculate that the antiangiogenic milieu associated with pregnancy (especially if preeclampsia occurs) sensitizes the gravid renal endothelium, thereby lowering the threshold at which blood loss may precipitate AKI. RCN does not fully belong within the continuum of endotheliosis-associated TMA, because overt preeclampsia is not a necessary prerequisite for its occurrence. Rather, RCN appears to result from a “double hit” involving endotheliosis together with hemorrhage and, in some cases, exposure to prothrombotic agents. Importantly, the topics addressed during MCC meetings extend far beyond identifying the cause and treatment of TMA and encompass broader peripartum management issues: optimal antihypertensive strategies before and after delivery; threshold of platelet transfusion if delivery is imminent; choice of obstetrical delivery technique and anesthesia; timing of resumption of prophylactic anticoagulation; and follow-up of AKI. It is likely that extreme phenotypes of endotheliosis, leading to both HELLP syndrome and AKI, represent an appropriate context for further studies evaluating, in a controlled manner, the potential benefit of targeted therapies. At present, angiogenic factors, and the complement pathway seem reasonable targets. There are indeed several explanations for why preeclampsia-related TMA extends to the kidney. First, sFlt-1–induced glomerular endotheliosis is a direct consequence of a deficiency in vascular endothelial growth factor signaling (known to cause TMA even in the absence of a placenta).25,35,36 Second, glomerular vulnerability to complement activation is heightened by the fact that endothelial synthesis of Factor H, the main inhibitor of complement, is also dependent on PlGF,26,27 also captured by sFlt1. Third, glomerular activity to complement activation is increased by the fact that free heme liberated by HELLP-asssociated intravascular hemolysis alters endothelial glycocalyx and prevents factor H adhesion to it.12 Independently from these considerations regarding the current nomenclature, our report has limitations. First, remote assessment of cases inherently carries certain limitations. Second, the composition of the group attending each MCC case conference varied because of its impromptu nature; experts were required to reorganize their schedules within hours to participate. Nevertheless, the number and diversity of specialists present ensured a balanced and well-considered approach to therapeutic decision-making. The therapeutic armamentarium has expanded in recent years, and pregnancy represents a particularly challenging context in which uncertainty regarding the efficacy and safety of newer agents remains substantial. Third, despite its strong negative predictive value for preeclampsia and therefore for severe endotheliosis, the sFlt-1/PlGF ratio was rarely measured by clinicians in a timely manner, leading us to advocate for its broader use in this context. Likewise, placental histology was unavailable at the time of the MCC discussion in the vast majority of cases. Fourth and finally, the possibility that aHUS was one of the principal reasons for convening the expert panel. We acknowledge that we cannot formally exclude the presence of true aHUS cases within this inaugural cohort, because genetic analyses, although frequently requested, were not available at the time of the discussions. In women with preserved ADAMTS13 activity, we often recommended an “armed” expectant management strategy, meaning that the use of eculizumab was temporarily deferred, rather than ruled out, for an additional 24 to 48 hours while assessing whether the TMA resolved following delivery alone. Conclusion The occurrence of TMA during pregnancy is rare but carries a high risk of maternal and fetal mortality. After 2 years of multidisciplinary discussions centered on severe and complex cases, we observed that active surveillance is recommended in the majority of cases; however, a change in management strategy was recommended in 26% of cases. In our view, this justifies the existence and continued development of this MCC, and argues for its duplication in other countries. Appendix List of Multidisciplinary Consultation Committee on Thrombotic Microangiopathy and Pregnancy Biology: Marie-Agnès Durey (Paris), Carine El Sissy (Paris), Véronique Frémeaux-Bacchi (Paris), Bérangère Joly (Paris), Emilie Jousselme (Lyon), Astrid Le Chatelier (Poissy), Marie-Nathalie Sarda (Lyon), Agnès Veyradier (Paris) ; Ob/Gyn: Anthony Atallah (Lyon), Anne-Sophie Boucherie (Poissy), Marie Carbonnel (Suresnes), Andrew Carlin (Bruxelles), Pierre-François Ceccaldi (Paris), David Desseauve (Grenoble), Paul Guerby (Toulouse), Anne Leostic (Dijon), Edouard Lecarpentier (Créteil), Thibaud Quibel (Poissy), Vassilis Tsatsaris (Paris) ; Hematology: Paul Coppo (Paris), Chloé Dhunputh (Bordeaux), Béata Hodossy (Bruxelles) ; Hepatology : Sophie Hillaire (Suresnes) ; Immunology : Francis Corazza (Bruxelles), Nathalie Ghorra (Bruxelles), Claire Leibler (Bordeaux), Carole Nagent (Bruxelles) ; Nephrology: Christelle Barbet (Tours), Laure Burguet (Pau), Concetta Catalano (Bruxelles), Eloise Colliou (Toulouse), Yahsou Delmas (Bordeaux), Vincent Dupont (Reims), Hélène El Hachem (Toulouse), Fadi Fakhouri (Lausanne), Christelle Fosso (Bruxelles), Marie Frimat (Lille), Clotilde Gaible (Toulouse), Anne-Sophie Garnier (Angers), Steven Grangé (Rouen), Anne Grunenwald (Poissy), Mary-Jane Guerry (Valenciennes), Jean-Michel Halimi (Tours), Alexandre Hertig (Suresnes), Florent Joly (Poitiers), Ioannis Katerinis (Paris), Moglie Le Quintrec (Montpellier), Yosu Luque (Paris), Valentin Maisons (Tours), Manon Martins (Rennes), Fleuria Meibody (Nancy), Laurent Mesnard (Paris), Olivier Moranne (Nîmes), Giorgina Piccoli (Le Mans), François Provot (Lille), Thomas Robert (Marseille), Marion Sallée (Marseille), Bénédicte Sautenet (Tours) , Aude Servais (Paris), Cécile Vigneau (Rennes), Florent Von Tokarski (Suresnes), Julien Züber (Paris) ; Internal Medicine: Raphaël Cauchois (Marseille), Nathalie Costedoat (Paris), Nelson-Georges Dengo (Rouen); Hélène Desmurs Clavel (Lyon), Laurent Gilardin (Bondy), Véronique Le Guern (Paris), Manon Marie (Lyon) ; Intensive care medicine: Anne-Sophie Bouthors (Lille), Nicolas Chardon (Lyon), Catherine Fischer (Paris), Romain Fort (Lyon), Vivien Guillotin (Bordeaux), Camille Guizard (Lille), Matthieu Jamme (Trappes), Mercé Jourdain (Lille), Nihal Martis (Nice), Frédéric Pène (Paris), Pierre Perez (Nancy), Renaud Prevel (Bordeaux), Mathias Rossignol (Paris), Marie Skarzynski (Orléans), and David Schnell (Angoulême). Disclosure Most of the authors report no conflict of interest, but YD, TR, SG, and AH report having served as consultants or invited speakers for the following pharmaceutical companies: Alexion, Alnylam, AstraZeneca, Amgen, Amicus, Astellas Pharma, Boehringer, Hemat Medical, Meditor, Menarini, Novartis, Samsung, Sanofi, Sobi, Takeda, and Vifor. Acknowledgments We would like to thank Prof. Christian Hervé and Dr. Henri-Corto Stoeklé for their valuable assistance regarding the ethical aspects of our organization, and all the experts of the TMA and pregnancy MCC. Footnotes Supplementary File (PDF) Supplementary Methods: Methodology of the radar chart shown in Figure 4. Figure S1. National territorial coverage of the MCC, including metropolitan France and overseas territories. Figure S2. Representation of the mulitdisciplinarity of the MCC “TMA and pregnancy” convened in 2023, 2024, and 2025. Table S1. TMA-box (biological tests recommended in complex cases of TMA occurring during pregnancy). Contributor Information Alexandre Hertig, Email: a.hertig@hopital-foch.com. French National Multidisciplinary Consultation Committee on Thrombotic Microangiopathy and Pregnancy: Marie-Agnès Durey, Carine El Sissy, Véronique Frémeaux-Bacchi, Bérangère Joly, Emilie Jousselme, Astrid Le Chatelier, Marie-Nathalie Sarda, Agnès Veyradier, Anthony Atallah, Anne-Sophie Boucherie, Marie Carbonnel, Andrew Carlin, Pierre-François Ceccaldi, David Desseauve, Paul Guerby, Anne Leostic, Edouard Lecarpentier, Thibaud Quibel, Vassilis Tsatsaris, Paul Coppo, Chloé Dhunputh, Béata Hodossy, Sophie Hillaire, Francis Corazza, Nathalie Ghorra, Claire Leibler, Carole Nagent, Christelle Barbet, Laure Burguet, Concetta Catalano, Eloise Colliou, Yahsou Delmas, Vincent Dupont, Hélène El Hachem, Fadi Fakhouri, Christelle Fosso, Marie Frimat, Clotilde Gaible, Anne-Sophie Garnier, Steven Grangé, Anne Grunenwald, Mary-Jane Guerry, Jean-Michel Halimi, Alexandre Hertig, Florent Joly, Ioannis Katerinis, Moglie Le Quintrec, Yosu Luque, Valentin Maisons, Manon Martins, Fleuria Meibody, Laurent Mesnard, Olivier Moranne, Giorgina Piccoli, François Provot, Thomas Robert, Marion Sallée, Bénédicte Sautenet, Aude Servais, Cécile Vigneau, Florent Von Tokarski, Julien Züber, Raphaël Cauchois, Nathalie Costedoat, Nelson-Georges Dengo, Hélène Desmurs Clavel, Laurent Gilardin, Véronique Le Guern, Manon Marie, Anne-Sophie Bouthors, Nicolas Chardon, Catherine Fischer, Romain Fort, Vivien Guillotin, Camille Guizard, Matthieu Jamme, Mercé Jourdain, Nihal Martis, Frédéric Pène, Pierre Perez, Renaud Prevel, Mathias Rossignol, Marie Skarzynski, and David Schnell Supplementary Material Supplementary File (PDF) Supplementary Methods: Methodology of the radar chart shown in Figure 4. Figure S1. National territorial coverage of the MCC, including metropolitan France and overseas territories. Figure S2. Representation of the mulitdisciplinarity of the MCC “TMA and pregnancy” convened in 2023, 2024, and 2025. Table S1. TMA-box (biological tests recommended in complex cases of TMA occurring during pregnancy). References Associated Data Supplementary Materials Supplementary File (PDF) Supplementary Methods: Methodology of the radar chart shown in Figure 4. Figure S1. National territorial coverage of the MCC, including metropolitan France and overseas territories. Figure S2. Representation of the mulitdisciplinarity of the MCC “TMA and pregnancy” convened in 2023, 2024, and 2025. Table S1. TMA-box (biological tests recommended in complex cases of TMA occurring during pregnancy).